Revised Prices of 1,364 Anti-Cancer Medicine Formulations Come into Effect; Patients to Save ₹3,540 Crore Annually

Patients undergoing cancer treatment across India are set to benefit from significant reductions in medicine prices as revised Maximum Retail Prices (MRPs) of 1,364 anti-cancer drug formulations come into effect from Monday, November 9. The price revisions are expected to generate annual savings of approximately ₹3,540.38 crore for consumers, providing financial relief to thousands of patients and their families dealing with the high cost of cancer treatment.

The National Pharmaceutical Pricing Authority (NPPA), operating under the Department of Pharmaceuticals, Ministry of Chemicals and Fertilizers, has implemented trade margin caps on 137 anti-cancer drugs. The decision follows recommendations made by an Expert Committee constituted by the Directorate General of Health Services (DGHS), Ministry of Health and Family Welfare, on October 17, 2026.

According to the latest information available as of November 8, a total of 85 pharmaceutical companies have reported revised MRPs for 1,364 anti-cancer formulations covering 121 drugs.

The price reductions represent a substantial change in the cost of several cancer medicines available in the Indian market. Of the brands that have reported revised prices, 679 have registered reductions exceeding 50 per cent. The highest reported reduction in MRP stands at 96.45 per cent.

The government estimates that these price reductions will collectively help consumers save ₹3,540.38 crore annually.

NPPA’s Trade Margin Regulation to Reduce Cancer Treatment Costs

The latest price revision is part of the government’s efforts to make essential medicines more affordable and improve access to cancer treatment.

Cancer treatment often involves prolonged medication, specialised therapies and regular medical monitoring, resulting in significant financial expenditure for patients and their families. The cost of anti-cancer medicines is an important component of the overall treatment burden, particularly for patients requiring long-term medication.

By capping trade margins on selected anti-cancer drugs, the NPPA aims to ensure that patients receive medicines at more affordable prices. The revised MRPs are applicable to the formulations covered under the latest exercise.

The reported figures indicate the scale of the price reductions. With 679 brands registering price cuts of more than 50 per cent and the highest reduction reaching 96.45 per cent, several anti-cancer formulations are expected to become considerably more affordable.

The participation of 85 pharmaceutical companies in reporting revised prices also reflects the implementation of the new pricing framework across multiple brands and formulations.

Consumers Advised to Check Revised MRP on Medicine Packs

The NPPA has advised consumers to verify the revised prices printed on medicine packaging before purchasing anti-cancer medicines.

Patients and their caregivers can also check the applicable prices through the Pharma Sahi Daam mobile application, which provides information on medicine prices.

The revised rates are also available through the official website of the National Pharmaceutical Pricing Authority at https://nppa.gov.in/.

The authority has clarified that no chemist, retailer or hospital pharmacy can charge consumers more than the applicable revised MRP. Consumers should therefore check the price printed on the medicine pack and ensure that they are not being charged an amount exceeding the prescribed retail price.

How to Report Overcharging by Chemists and Hospitals

To strengthen consumer protection and ensure compliance with the revised prices, the NPPA has provided grievance redressal mechanisms for patients and consumers.

In cases where a chemist, retailer or hospital pharmacy charges more than the revised MRP, consumers can register complaints through the Pharma Jan Samadhan portal.

Consumers can also contact the NPPA helpline at 1800-111-255 to report overcharging or other medicine pricing-related grievances.

The authority has encouraged patients and their families to remain aware of the revised MRPs and report violations to the appropriate authorities.

Major Relief for Cancer Patients and Their Families

The implementation of revised prices for 1,364 anti-cancer formulations marks an important development in the regulation of medicine prices in India.

With estimated annual consumer savings of ₹3,540.38 crore, the initiative is expected to ease part of the financial burden associated with cancer treatment. The reductions across hundreds of brands could particularly benefit patients who depend on expensive medicines for extended treatment periods.

The government initiative also highlights the role of the NPPA in monitoring medicine prices and regulating trade margins to improve affordability.

As the revised MRPs come into effect nationwide from November 9, patients are advised to check the prices of their prescribed medicines through official channels and ensure that pharmacies follow the new pricing requirements.